In a phase 2 trial of 485 adults with obesity without type 2 diabetes, once-weekly petrelintide (1–9 mg) reduced bodyweight by 7·9–9·8% at 28 weeks vs 1·7% with placebo (differences −6·2 to −8·1 points); nausea occurred in 20% vs 6%.
RCTn = 493
Garvey et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial